Osteonecrosis of the Femoral Head: Current Concepts in Diagnosis, Staging and Treatment
Sports Traumatology and Arthroscopy · 2026
DOI: 10.14744/sta.2026.26489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sports Traumatology and Arthroscopy, 2026. Verfasst von Ekin Barış Demir und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Osteonecrosis of the femoral head (ONFH) is a progressive disorder characterized by ischemiainduced death of the subchondral bone, most commonly affecting young and active individuals.More than one-third of patients have a history of corticosteroid use, while approximately 20% of cases are considered idiopathic.In the early stages, the disease may remain clinically asymptomatic; however, with progression, patients typically develop hip or groin pain accompanied by limitation of hip abduction and internal rotation.Treatment strategies are determined according to the stage of the disease and include conservative management, joint-preserving procedures, and salvage procedures.The aim of this review is to comprehensively summarize the etiology, pathophysiology, diagnostic methods, staging systems, and current treatment approaches for femoral head avascular necrosis.
Zitieren
APA
Demir, E. B., Barça, F., Danışman, M., Akdoğan, M., Ateş, Y., & Atilla, H. A. (2026). Osteonecrosis of the Femoral Head: Current Concepts in Diagnosis, Staging and Treatment. Sports Traumatology and Arthroscopy. https://doi.org/10.14744/sta.2026.26489
Vancouver
Demir EB, Barça F, Danışman M, Akdoğan M, Ateş Y, Atilla HA. Osteonecrosis of the Femoral Head: Current Concepts in Diagnosis, Staging and Treatment. Sports Traumatology and Arthroscopy. 2026. doi:10.14744/sta.2026.26489
BibTeX
@article{Demir2026,
author = {Demir, Ekin Barış and Barça, Fatih and Danışman, Murat and Akdoğan, Mutlu and Ateş, Yalım and Atilla, Halis Atıl},
title = {Osteonecrosis of the Femoral Head: Current Concepts in Diagnosis, Staging and Treatment},
journal = {Sports Traumatology and Arthroscopy},
year = {2026},
doi = {10.14744/sta.2026.26489}
}
EUVIMED